Ascendiant Capital Markets initiates coverage on StemCells (STEM +1.7% to $2.44) with a "Buy"...
Ascendiant Capital Markets initiates coverage on StemCells (STEM +1.7% to $2.44) with a "Buy" recommendation and a price target of $2.60. "We believe that StemCells is an intriguing speculative small cap investment story," Ascendiant writes. "The Company is breaking new ground in its development of novel stem cell therapies."
From other sites
at 4-traders.com (Mar 24, 2015)
at Nasdaq.com (Dec 15, 2014)
at MarketWatch.com (Feb 12, 2013)
at Fox Business (Aug 30, 2012)
at MarketWatch.com (Jul 5, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs